InvestorsHub Logo

farrell90

08/13/21 11:16 AM

#370324 RE: Longpicker #370300

No.. next they will review the data case by case and site by site looking to confirm the data reported.

"The subject database remains blinded with the current emphasis on confirmation of all data entered at study sites, as well as completion of source data verification and the necessary checks and reviews by the data management vendor in preparation of database lock.

Following database lock and transfer to the biostatistics vendor, analysis of the unblinded data from the clinical trial will begin to assess Brilacidin’s performance, against placebo, across primary, secondary, and other endpoints. Topline results are anticipated to be available one week after database lock, with full analysis to follow.

“Our team is as excited as anyone to learn the results of our Brilacidin COVID-19 clinical trial. Everything is advancing per industry norms and standards,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We look forward to sharing Brilacidin topline data in treating COVID-19 as soon as we have it in hand."

http://www.ipharminc.com/press-release/2021/8/12/last-patient-last-visit-completed-in-innovation-pharmaceuticals-phase-2-clinical-trial-of-brilacidin-for-covid-19-trial-database-undergoing-review-in-preparation-for-database-lock

GLTA, Farrell

LIVED

08/13/21 11:18 AM

#370325 RE: Longpicker #370300